Phillip Wong, PhD (Core Head)
Office phone:
646-888-3157 (General Inquiries)
646-888-3514 (Philip Wong)
Email:
[email protected]
The primary research function of the Immune Monitoring Facility is to develop and run standardized immune monitoring assays for cancer clinical trial samples received and processed within the core. These assays are implemented to quantify immune responses and characterize cell populations and soluble proteins of interest in patients receiving experimental therapies. The results may help elucidate biomarkers of clinical outcomes following treatment.
The facility is well equipped to support the research endeavors of investigators wishing to performing immune monitoring on the serial samples banked for their studies. Currently it supports over 30 active clinical studies and receives approximately 200 clinical samples per month. The facility utilizes state-of-the-art immune monitoring technologies in support of biomarker discovery efforts, including high dimensional flow cytometry to characterize various cell subsets and their activation/functional status; multiplex immunoassay platforms to measure cytokines and other soluble protein biomarkers; serological methods to detect antibodies to a variety of tumor-associated antigens; and protein microarrays that allow a seromics approach for interrogating immune reactivity to a large subset of the human proteome.
Our main objectives are to:
- Coordinate immune monitoring for clinical trials of new cancer immunotherapies
- Develop, optimize, and validate new technologies for immune monitoring
- Provide standardized and modern immune-based assays to monitor patients receiving novel immunotherapy
- Promote the development of new biomarkers
